Get the Stockscreener App
3.63
3.20%
-0.12
After Hours:
3.70
0.07
+1.93%
Nrx Pharmaceuticals Inc stock is traded at $3.63, with a volume of 926.63K.
It is down -3.20% in the last 24 hours and down -2.68% over the past month.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
See More
Previous Close:
$3.75
Open:
$3.81
24h Volume:
926.63K
Relative Volume:
0.80
Market Cap:
$155.37M
Revenue:
$1.23M
Net Income/Loss:
$-28.62M
P/E Ratio:
-2.3124
EPS:
-1.5698
Net Cash Flow:
$-14.11M
1W Performance:
-13.16%
1M Performance:
-2.68%
6M Performance:
+62.05%
1Y Performance:
+21.00%
1-Day Range:
$3.57
$3.89
1-Week Range:
$3.57
$4.64
52-Week Range:
$1.62
$5.055
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Name
Nrx Pharmaceuticals Inc
Sector
Industry
Phone
484-254-6134
Address
1201 ORANGE STREET, WILMINGTON
Compare NRXP vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
3.63 | 160.50M | 1.23M | -28.62M | -14.11M | -1.5698 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Initiated | H.C. Wainwright | Buy |
| Apr-02-25 | Initiated | BTIG Research | Buy |
Nrx Pharmaceuticals Inc Stock (NRXP) Latest News
NRX Pharmaceuticals Inc (NRXP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NRX Pharmaceuticals Inc (NRXP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NRX Pharmaceuticals Inc (NRXP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NRX Pharmaceuticals Inc (NRXP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NRX Pharmaceuticals Inc (NRXP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NRX Pharmaceuticals Inc (NRXP) Cash Flow - TradingKey
NRXP|NRX Pharmaceuticals Inc|Price:3.620|Chg%:-0.130 - TradingKey
TradingKey - TradingKey
NRX Pharmaceuticals, Inc. Revenue Breakdown – MUN:B1Q - TradingView
NRX Pharmaceuticals, Inc. Revenue Breakdown – FWB:B1Q - TradingView
NRX Pharmaceuticals Inc (B1Q.HM) stock price, news, quote and history - Yahoo Finance UK
NRX Pharmaceuticals Inc (B1Q.HM) stock major holders - Yahoo Finance UK
NRX Pharmaceuticals Inc (NRXP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NRx Pharmaceuticals Selected by DARPA for Innovative SPARC-TMS Clinical Trial to Treat Depression - Minichart
Market Sentiment Around Loss-Making NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) - Sahm
NRXP Stock Price, Quote & Chart - ChartMill
Is NRx Pharmaceuticals, Inc. (NRXP) Stock Positioned for Growth Through Depression and PTSD Treatment Innovation? - Yahoo Finance
NRX Pharmaceuticals Inc (NRXPW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Equity in earnings of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Enterprise value to revenue forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP - TradingView
NRXP Should I Buy - Intellectia AI
First Patients Treated via FDA-Cleared Transcranial Magnetic Stimulation, Plus FDA Grant on D-Cycloserine-Based Drug for Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - Barchart.com
NRx Pharmaceuticals, Inc.(NasdaqCM:NRXP) dropped from Russell 3000E Growth Benchmark - marketscreener.com
NRx Pharmaceuticals, Inc.(NasdaqCM:NRXP) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Price to book forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP - TradingView
Price to book forward of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Price to sales forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP - TradingView
Enterprise value to revenue forward of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Price to sales forward of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Enterprise value to EBITDA forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP - TradingView
Price to earnings forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP - TradingView
Enterprise value to EBIT forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP - TradingView
Enterprise value to EBIT forward of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Price to earnings forward of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
NRX Pharmaceuticals(NRXP) Stock Options Chain | Quotes & News - Moomoo
H.C. Wainwright Keeps Their Buy Rating on NRX Pharmaceuticals (NRXP) - The Globe and Mail
NRx Pharmaceuticals Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute - The Manila Times
NRX Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:NRXP) - TradingView
NRx Pharmaceuticals responds to Kadima dispute claims - Investing.com UK
NRx Pharmaceuticals responds to Kadima dispute claims By Investing.com - Investing.com South Africa
NRx subsidiary begins AI-guided TMS treatments in Florida - Investing.com UK
NRXP Forecast — Price Target — Prediction for 2027 - TradingView
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System - GlobeNewswire
Kadima sues NRx Pharmaceuticals over failed acquisition deal - Investing.com UK
Kadima Neuropsychiatry Institute Sues NRX Pharmaceuticals Over Breach of Acquisition Contract - marketscreener.com
Kadima sues NRx Pharmaceuticals over failed acquisition deal By Investing.com - Investing.com South Africa
Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition - Business Wire
NRx Pharmaceuticals, Inc. (NRXP) reports Q1 loss, lags revenue estimates - MSN
ZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics - Sahm
Nrx Pharmaceuticals Inc Stock (NRXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):